Eagle Pharmaceuticals announced today that its dantrolene sodium injectable suspension (brand name Ryanodex) has received a patent for the treatment of exertional heat stroke, which will provide coverage through 2023. Patent ‘460 brings the company’s IP surrounding Ryanodex to four issued patents. As the patent coverage surrounding the company’s best-in-class formulation solidifies, Eagle will initiate a pilot study for the treatment of exertional heatstroke over the next several months. Given the acute nature of exertional heat stroke cases, we anticipate data from the pilot program to be available by year end, pending the initiation of clinical work this summer.